Association Between Immunotherapy Infusion Time and Survival Outcomes in Melanoma

Immune checkpoint inhibitor immunotherapieshave transformed cancer treatment by substantially improving survival and response rates. One topic attracting attention in oncology is whether the time of day a medicine is administered affects outcomes. Research shows that biological processes are regulated over a 24-hour cycle called a circadian rhythm .

This biological clock can influence hormone release, immune activity, and cell renewal. Giving cancer medicines at times aligned with biological rhythms might therefore improve effectiveness. However, studies of circadian factors in immunotherapy remain limited, and this topic has not been adequately explored.

Terms Related to Cancer Treatment Timing:

• Chronotherapy: Scheduling treatment to align with circadian rhythms.
• Circadian Medicine: Integrating circadian factors into medical treatment.
• Treatment Timing: When treatment is administered.
• Chronomodulation of Therapy: Modifying treatment timing.

A Recent Study: Treatment Timing in Melanoma

Published on May 16, 2023, in Immunotherapy , this study examined advanced melanoma and the potential effects of immunotherapy timing on overall survival (OS) and progression-free survival (PFS) to explore the relationship between biological clocks and outcomes. It aimed to provide evidence supporting consideration of individual biological rhythms in treatment planning.

1. The Immune System's Biological Clock

Circadian rhythm is an internal clock that regulates biological processes over a 24-hour cycle. Immune cells are known to respond to this rhythm, potentially influencing immunotherapy response. Previous studies have shown an important role for circadian timing in chemotherapy and radiotherapy, but evidence on timing effects in immunotherapy and immune cells remains insufficient.

2. Study Aim:

This retrospective study investigated how the timing of the first four immunotherapy infusions affected survival in advanced/metastatic melanoma.

The hypothesis was that morning infusions would produce better overall and progression-free survival.

3. Methods:

Study Design and Participants:

The study enrolled patients starting immunotherapy between May 2015 and May 2021 at Kingston Health Sciences Centre, Canada: 121 patients with advanced melanoma . Participants were divided into two groups according to their first four infusion times:

• Early group: At least one of the first four infusions occurred before 13:00.

• Late group: All of the first four infusions occurred after 13:00.

Data Collection and Analysis:

Patient demographics, tumor stage, treatment regimens, and survival were examined in detail. Kaplan–Meier survival curves and Cox regression were used for statistical analysis.

4. Findings:

• Overall Survival (OS): Median survival was 5.5 months in patients whose first four infusions were all in the afternoon, versus 24.9 months in the morning-infusion group (p < 0.001).

• Progression-Free Survival (PFS): Median progression-free survival was 3.3 months in the afternoon group and 7.6 months in the morning group (p = 0.009).

• Immunotherapy Side Effects: The morning-infusion group experienced a higher rate of immunotherapy side effects (72%versus 43%; p = 0.008).

Multivariable Analysis: The morning-infusion group had an approximately 58% lower mortality risk. This association remained statistically significant after controlling for factors such as performance status and comorbidities.

Commentary

The findings suggest that immunotherapy timing significantly affects clinical outcomes. The importance of the first four infusion times particularly suggests that the immune response at the start of treatment is critical . This supports the idea that modifying immunotherapy timing could improve effectiveness.

However, the higher side-effect rate with morning infusions suggests that a stronger immune response may improve tumor control while also damaging healthy tissues. Monitoring and managing side effects should be part of clinical protocols.

The findings suggest a possible survival advantage from morning immunotherapy. Treatment timing may be a simple, cost-free strategy to improve patient-centered outcomes.

Future Research:

• Investigating timing effects in other cancers.
• Developing personalized approaches using circadian biomarkers.
• Confirming the findings in prospective randomized controlled trials.

Clinical Practice Suggestion:

Morning infusions may be prioritized in treatment planning, particularly at the start of treatment. This could improve immunotherapy effectiveness and patient survival.